Back to Search
Start Over
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open‐Label, Active‐Treatment Extension Study
- Source :
- Arthritis & Rheumatology. 72:2147-2158
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- OBJECTIVE: To evaluate the long-term efficacy and safety of canakinumab and explore prediction of response in patients with systemic juvenile idiopathic arthritis (JIA) with or without fever at treatment initiation. METHODS: At enrollment, patients with active systemic JIA (ages 2 to
- Subjects :
- Male
medicine.medical_specialty
Adolescent
Fever
Immunology
Arthritis
Antibodies, Monoclonal, Humanized
Young Adult
Juvenile Arthritis Disease Activity Score
Rheumatology
Paediatric Rheumatology International Trials Organisation (PRINTO), the Pediatric Rheumatology Collaborative Study Group (PRCSG)
Internal medicine
medicine
Humans
Immunology and Allergy
Child
business.industry
Odds ratio
medicine.disease
Arthritis, Juvenile
Confidence interval
Discontinuation
Canakinumab
Treatment Outcome
Antirheumatic Agents
Child, Preschool
Female
business
Glucocorticoid
medicine.drug
Subjects
Details
- ISSN :
- 23265205 and 23265191
- Volume :
- 72
- Database :
- OpenAIRE
- Journal :
- Arthritis & Rheumatology
- Accession number :
- edsair.doi.dedup.....187dbbececdbd177cb016b88cf180fdf
- Full Text :
- https://doi.org/10.1002/art.41436